X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Radicava ORS (edaravone) is a free radical scavenger available in the form of oral suspension, which is approved by USFDA for the treatment of amyotrophic lateral sclerosis.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava ORS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 08, 2024
Details:
Under the expiration of the agreement, Daiichi will transfer the distribution rights of Tenelia (teneligliptin) to Mitsubishi and will end the information provision activities to medical institutions for all products, which are currently jointly conducted with Mitsubishi.
Lead Product(s): Teneligliptin Hydrobromide
Therapeutic Area: Endocrinology Product Name: Tenelia
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Daiichi Sankyo
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination March 04, 2024
Details:
ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: ND0612
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuroDerm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
Mounjaro (tirzepatide) is a GIP receptor and GLP-1 receptor agonist, which enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucosedependent manner.
Lead Product(s): Tirzepatide
Therapeutic Area: Endocrinology Product Name: Mounjaro
Highest Development Status: ApprovedProduct Type: Peptide
Recipient: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava ORS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 23, 2023
Details:
Radicava ORS (edaravone) is a free radical scavenger used to delay the progression of amyotrophic lateral sclerosis (ALS) due to the therapeutic effect of its known antioxidant properties as oxidative stress kills neurons in patients with ALS.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava ORS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2023
Details:
RADICAVA ORS® (edaravone) is an ORAL administration option of RADICAVA (edaravone), an ALS treatment shown to slow the loss of physical function. RADICAVA ORS is taken daily for 14 consecutive days followed by a 14-day drug-free period for the initial treatment cycle.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava ORS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Details:
In clinical trials, the most common adverse reactions (≥10%) reported in RADICAVA-treated patients were contusion, gait disturbance and headache. In an open-label study, fatigue was also observed in 7.6% of patients receiving RADICAVA ORS (edaravone).
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava ORS
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2022
Details:
The U.S. Food and Drug Administration (FDA) approved RADICAVA® (edaravone) and the oral formulation RADICAVA ORS® (edaravone) for the treatment of amyotrophic lateral sclerosis (ALS) and is administered in 28-day cycles by IV infusion.
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 15, 2022
Details:
RADICAVA® (edaravone) in a real-world setting during the first three years of availability in the United States (U.S.) for the treatment of amyotrophic lateral sclerosis (ALS).
Lead Product(s): Edaravone
Therapeutic Area: Neurology Product Name: Radicava
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
